Beijing Kawin Technology Share-holding Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 12.53%

Beijing Kawin Technology Share-holding Co Ltd (688687) has an Asset Resilience Ratio of 12.53% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beijing Kawin Technology Share-holding C leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CN¥337.92 Million
≈ $49.45 Million USD Cash + Short-term Investments

Total Assets

CN¥2.70 Billion
≈ $394.79 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Beijing Kawin Technology Share-holding Co Ltd's Asset Resilience Ratio has changed over time. See 688687 equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Beijing Kawin Technology Share-holding Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Beijing Kawin Technology Share-holding C worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥337.92 Million 12.53%
Total Liquid Assets CN¥337.92 Million 12.53%

Asset Resilience Insights

  • Moderate Liquidity: Beijing Kawin Technology Share-holding Co Ltd has 12.53% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Beijing Kawin Technology Share-holding Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing Kawin Technology Share-holding Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 10.93%
CSL Ltd
AU:CSL
Biotechnology 0.41%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
HLB Co. Ltd
KQ:028300
Biotechnology 0.72%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Biotechnology 87.20%
Tourmaline Bio Inc.
NASDAQ:TRML
Biotechnology 77.17%
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
Biotechnology 16.35%

Annual Asset Resilience Ratio for Beijing Kawin Technology Share-holding Co Ltd (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Beijing Kawin Technology Share-holding Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 10.29% CN¥287.50 Million
≈ $42.07 Million
CN¥2.79 Billion
≈ $408.72 Million
-3.12pp
2024-12-31 13.41% CN¥350.87 Million
≈ $51.34 Million
CN¥2.62 Billion
≈ $382.75 Million
-1.51pp
2023-12-31 14.92% CN¥365.33 Million
≈ $53.46 Million
CN¥2.45 Billion
≈ $358.25 Million
-8.21pp
2022-12-31 23.13% CN¥511.12 Million
≈ $74.79 Million
CN¥2.21 Billion
≈ $323.35 Million
+19.46pp
2021-12-31 3.67% CN¥80.00 Million
≈ $11.71 Million
CN¥2.18 Billion
≈ $318.67 Million
--
pp = percentage points

About Beijing Kawin Technology Share-holding Co Ltd

SHG:688687 China Biotechnology
Market Cap
$402.98 Million
CN¥2.75 Billion CNY
Market Cap Rank
#13536 Global
#4086 in China
Share Price
CN¥16.11
Change (1 day)
-2.95%
52-Week Range
CN¥15.95 - CN¥38.59
All Time High
CN¥40.56
About

Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more